logo
Plus   Neg
Share
Email
Comment

Aurobindo Pharma Gets Final Approvals For Quetiapine Fumarate Tablets

Manufacturer of generic pharmaceuticals and active pharmaceutical ingredients Aurobindo Pharma Ltd. announced that the company had obtained final approvals from the US Food & Drug Administration or US FDA to market Quetiapine Fumarate tablets 25mg, 50mg, 100mg, 150mg, 200mg, 300mg and 400mg.

Quetiapine Fumarate tablets 25mg, 50mg, 100mg, 150mg, 200mg, 300mg and 400mgare the generic equivalent of AstraZeneca LP's Seroquel tablets 25mg, 50mg, 100mg, 150mg, 200mg, 300mg and 400mg. These tablets are indicated for the treatment of serious psychotic disorders such as Schizophrenia and Bipolar Disorder and fall under the Neurological (CNS) therapeutic category.

The company said the product had been approved out of Unit III facility in Hyderabad, India.

Aurobindo now has a total of 147 ANDA approvals (118 final approvals and 29 tentative approvals)from US FDA.

AT the BSE, Aurobindo Pharma shares are currently trading at Rs.116.55, up 1.66 percent from the previous close.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

More Breaking News

0 Articles
Editors Pick
Cannae Holdings, Inc. said Wednesday that its portfolio company, Ceridian HCM Holding Inc., has confidentially filed for an initial public offering. Ceridian HCM, a provider of human resources software and services, filed a draft registration statement on Form S-1 to the U.S. Securities and Exchange Commission relating to the proposed IPO of its common stock. Goldman Sachs Group Inc. on Wednesday reported a loss for the fourth quarter, reflecting lower trading revenue in fixed income, currencies and commodities as well as a charge related to the recent U.S. tax reform. However, both adjusted earnings per share and revenues for the quarter topped analysts' expectations. Bank of America Corp. (BAC) reported a profit for the fourth-quarter of 2017 that declined about 50 percent from last year, hurt by a charge of $2.9 billion or $0.27 per share, related to the Tax Cuts and Jobs Act.
comments powered by Disqus
Follow RTT